Physician profile
Jonathan Olson
NPI 1174783385
$3,638.23
in general payments reported to CMS, 2019-2025
23 companies · $2,187 in 2025
The $2,187 reported for 2025 was more than what 90% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $368 · 2020: $60.62 · 2021: $121 · 2022: $181 · 2023: $59.68 · 2024: $662 · 2025: $2,187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,731 · Education: $177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,730.99 |
| Education | $177.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $656.57 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $355.32 | 2022-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $326.43 | 2020-2025 | Odomzo, Blu-U |
| Abbvie INC. | $288.82 | 2024-2025 | |
| Janssen Biotech, INC. | $264.69 | 2025 | Tremfya |
| Ucb, INC. | $257.58 | 2025 | Bimzelx |
| Leo Pharma INC. | $223.08 | 2024-2025 | Adbry |
| Genentech USA, INC. | $198.88 | 2019-2024 | Erivedge |
| Lilly USA, LLC | $175.30 | 2024-2025 | Ebglyss, Taltz, Olumiant |
| Pfizer INC. | $162.24 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $122.93 | 2025 | |
| Incyte Corporation | $117.85 | 2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $97.34 | 2024-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $79.21 | 2024-2025 | Sotyktu |
| Organogenesis INC. | $76.71 | 2023-2025 | Puraply, Via Matrix, Simplimax |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $51.85 | 2025 | Otezla |
| Almirall LLC | $40.03 | 2021-2022 | |
| Dusa Pharmaceuticals, INC. | $31.26 | 2019 | |
| Botanix Sb INC | $30.99 | 2025 | Sofdra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $22.12 | 2025 | Cabtreo |
| Journey Medical Corporation | $21.98 | 2025 | |
| Biofrontera INC. | $19.41 | 2024 | Xepi, Bf-Rhodoled, Rhodoled Xl |
| Paratek Pharmaceuticals, INC. | $17.64 | 2025 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Olson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.